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Abstract
Introduction—Presence of cerebrovascular pathology may increase the risk of clinical diagnosis
of AD.
Methods—We examined excess risk of incident clinical diagnosis of AD (probable and possible
AD) posed by the presence of lacunes and large infarcts beyond AD pathology using data from the
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Statistical Modelling of Aging and Risk of Transition (SMART) study, a consortium of
longitudinal cohort studies with over 2000 autopsies. We created six mutually exclusive pathology
patterns combining three levels of AD pathology (low, moderate or high AD pathology) and two
levels of vascular pathology (without lacunes and large infarcts or with lacunes and/or large
infarcts).
Results—The coexistence of lacunes and large infarcts results in higher likelihood of clinical
diagnosis of AD only when AD pathology burden is low.
Discussion—Our results reinforce the diagnostic importance of AD pathology in clinical AD.
Further harmonization of assessment approaches for vascular pathologies is required.
Keywords

Author Manuscript

Alzheimer’s disease pathology; vascular pathology; SMART consortium; Population Attributable
Risk %

BACKGROUND

Author Manuscript
Author Manuscript

Epidemiological studies have shown that reducing vascular risk factors could yield large
decreases in the prevalence of all-cause dementia [1, 2] as well as Alzheimer’s disease (AD)
[3, 4]. Studies have also shown the significance of vascular disease in the pathogenesis of
AD [5-10] and that comorbid cerebrovascular pathology plays a key role for clinical
expression of dementia, especially among the oldest old [11, 12] where mixed pathology is
common [13, 14]. Self-reported vascular disease or its risk factors used in most
epidemiological studies give important information regarding the potential contribution of
these factors on risk of receiving a clinical diagnosis of probable or possible AD (henceforth
“clinical AD” in this paper), but a more precise assessment of etiology and factors
associated with clinical AD may be provided by autopsy confirmed evidence. However, it is
often difficult to obtain a large enough pre-morbidly characterized post mortem sample to
allow examination of the magnitude of additional risks for clinical AD posed by coexisting
vascular factors, especially among non-clinical cohorts. In this study, we used the Statistical
Modelling of Aging and Risk of Transition (SMART) study, which is a consortium of highquality longitudinal studies of aging and cognition, established for the purpose of
characterizing risk and protective factors associated with subtypes of age-associated mixed
neuropathologies [15]. Our aim was to quantify the excess risk of receiving a clinical AD
diagnosis associated with the pathology-confirmed presence of lacunes (small artery
infarcts) and one or more large artery cerebral infarct(s), beyond AD signature pathology
defined by neuritic plaques scores [16] and Braak & Braak neurofibrillary tangle (NFT)
stage [17]. We created six mutually exclusive pathology patterns: (1) Low AD pathology
without lacunes and large infarcts, (2) Low AD pathology with lacunes and/or large infarcts,
(3) Moderate AD pathology without lacunes and large infarcts, (4) Moderate AD pathology
with lacunes and/or large infarcts, (5) High AD pathology without lacunes and large infarcts,
and (6) High AD pathology with lacunes and/or large infarcts. The aim of this study is not to
delineate the causal relationship between cerebrovascular factors and the development of
hallmark AD pathologies, but rather to assess the Population Attributable Risk % (PAR%) of
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lacunes and large infarcts on having clinical AD, i.e., the proportion of clinical AD
incidence that could be eliminated by preventing lacunes and large infarcts.

METHODS
Participants

Author Manuscript

The SMART data consortium and the longitudinal cohort studies included in the data set are
explained in detail elsewhere [15]. Based on the availability of necessary variables,
participants from the following 8 projects contributed by 4 centers in the USA were included
in the present study: the Oregon Brain Aging Study I and II [18], the African American
Dementia Project [15], and the Klamath Exceptional Aging Project [19] from Oregon Health
& Science University, Portland, Oregon; the Religious Orders Study [20] and the Rush
Memory and Aging Project [21] from the Rush University, Chicago, Illinois; the Memory
and Aging Project [22] from Washington University, St Louis, Missouri; and the
Biologically Resilient Adults in Neurological Studies [23] from University of Kentucky,
Lexington, Kentucky. We note that these four centers are Alzheimer’s Disease Centers
(ADCs), although the cohorts mentioned above are recruited from communities. Institutional
Review Boards at each research center approved all study procedures, and all participants
provided written informed consent.
Harmonization of variables

Author Manuscript

SMART investigators reviewed data collection protocols from each participating center and
identified elements that were common to at least two centers. Data templates, based on the
methods established by the National Alzheimer’s Coordinating Center (NACC) [24], which
aggregates data collected by ADCs, were developed to request standardized data elements
from each center. Data templates for demographic information, genetics and family history
of dementia, clinical diagnosis, motor function, medical history, medication use, physical
examination, and neuropathology were the same for all centers. All centers used similar
criteria for diagnoses of all-cause dementia (DSM-III-R [25]or DSM-IV[26]) and clinical
AD [27]. However, clinical diagnoses of mild cognitive impairment (MCI) were less
standardized because some studies were initiated before MCI diagnostic criteria were
established, and MCI diagnostic criteria have evolved over time. Therefore, in the current
study, we are limiting our outcome of interest to AD, not MCI or MCI due to AD.
Pathology variables

Author Manuscript

Neuropathological assessments were performed blind to clinical data. The component
neuropathological data were coded according to NACC guidelines, as described previously
(see https://www.alz.washington.edu/nonmember/np/rdd_np.pdf). We created six mutually
exclusive pathology patterns: (1) Low AD pathology without lacunes and large infarcts, (2)
Low AD pathology with lacunes and/or large infarcts, (3) Moderate AD pathology without
lacunes and large infarcts, (4) Moderate AD pathology with lacunes and/or large infarcts, (5)
High AD pathology without lacunes and large infarcts, and (6) High AD pathology with
lacunes and/or large infarcts. We used the Consortium to Establish a Registry in Alzheimer’s
Disease [CERAD] neuritic plaque rating [16] and Braak & Braak NFT stages [17] to define
low, moderate and high AD pathology. Low AD pathology was defined as Braak NFT stage
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of none, stage I or II with CERAD plaque stage of none or sparse; high AD pathology was
defined as Braak NFT stage V or VI with CERAD plaque stage of moderate or frequent.
Moderate AD pathology was defined as those cases falling between the low and high groups
(details shown in Table 2, discussed later). Large infarcts were defined as those with
maximum diameter greater than 1 cm that were territorial in nature and attributed to
compromise involving large- or medium-sized meningocerebral vessels; lacunes were
defined as infarcts or hemorrhages 1 cm or less in diameter due to small parenchymal
vascular disease and most commonly encountered in the deep gray matter.
Covariates

Author Manuscript

Participant age at death (centered at 85 years), sex (female=1, male=0), years of education,
APOE-ε4 carrier status (at least oneAPOE-ε4 allele=1, no APOE-ε4 alleles=0), Lewy body
pathology presence (yes=1, no=0), and indicators for center (Rush, Kentucky, Washington
University, with Oregon as the reference group) were considered.
Statistical Analyses

Author Manuscript

We examined characteristics associated with having an autopsy (i.e., autopsy data not
missing) to assess possible selection bias. Group differences (with or without autopsy) were
examined first by univariate analysis using Student’s t-test or Wilcoxon ranked sum test for
continuous variables and the Pearson chi-square test for categorical variables, and then by
multivariate analysis using a logistic regression model with the outcome being presence or
absence of autopsy data. The risks of developing a clinical diagnosis of AD associated with
the six pathology patterns were examined using a Cox proportional hazards model with age
as the time scale. To examine variability across centers, we ran the models with (model 1)
and without (model 2) center indicators. Proportionality assumptions were examined
through visual inspection of log-log survival curves, and analytical assessments [28] using
covariates-by-time interactions in the Cox model. Using the coefficients obtained from the
models and prevalence of each of the six pathology patterns, we estimated the Population
Attributable Risk % (PAR%). PAR% is determined by both the prevalence of a risk factor
and the magnitude of its effect.
Sensitivity analysis using multiple imputation approaches

Author Manuscript

As a sensitivity analysis, we imputed missing pathology data using multiple imputation
approaches and examined whether conclusions differed if we used the imputed data.
Preliminary analyses showed that missingness among pathology data was dependent on
observed data, and therefore we assumed that our data were missing at random (MAR [29]).
In order to increase precision of imputed pathology patterns, we also imputed age of onset of
dementia and clinical AD, if these data were missing. There were several challenges to our
imputation approaches including: (1) missingness occurred in multiple different types of
variables, including binary (yes/no) and continuous (ex: age of onset) variables, (2) there
were boundary restrictions, e.g., age of clinical AD onset must occur later than the last
observed date when a clinical diagnosis of normal cognition was provided, and (3) there
were logical restrictions, e.g., clinical AD onset could be imputed only if participants had
dementia onset (either imputed or actually observed). Therefore, we applied a sequential
regression multiple imputation approach (SRMI)[30-32]), also known as multivariate
Alzheimers Dement. Author manuscript; available in PMC 2018 June 01.
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imputation by chained equations (MICE, [33]), to impute these missing values. Briefly, the
SRMI approach uses an iterative algorithm with a sequence of fully conditionally specified
models. It’s particularly useful in our study as SRMI can easily handle the challenges
mentioned above. The following variables were used in SRMI: completely observed
variables (without missing data) used for imputation included gender, education, age at
death, clinical diagnosis at last clinical assessment before death, duration of follow-up,
duration between the last clinical assessment and death, center indicators and APOE-ε4
information. Variables imputed sequentially included age at dementia onset, age at AD onset
and pathology variables (Braak and CERAD scores, Lewy body pathology, lacunes and large
infarcts). We closely monitored algorithm convergence as reported in Results. All analyses
were conducted using statistical software R (version 3.1.3) and SAS 9.3® (SAS Institute,
Inc., Cary, NC).

Author Manuscript

RESULTS

Author Manuscript

Out of 5405 participants with intact cognition at baseline, 1673 participants died (Figure 1).
Among them, 1566 participants had APOE information. Among them, 1054 participants had
an autopsy with complete pathology information and were used in the primary analyses. An
additional 512 participants with none or missing autopsy variables (Figure 1) were also used
for our sensitivity analysis where we imputed autopsy data. The mean (standard deviation,
range) baseline age of the full sample (n=1566 participants) was 79.7 years (7.2, 59.5 –
101.9), mean age at death was 88.5 years (7.2, 61.6 – 107.9), and 54.4% were women.
Average observed duration of follow-up to death was 8.5 years (5.0) and average time from
the last assessment to death was 1.6 years (2.1). Table 1 shows the characteristics of the
participants with and without autopsy based on univariate analyses. Those without autopsy
were older (p=0.01), more likely to be white (vs. non-white) (p<0.001), lower years of
education (p<0.001), had shorter duration of follow-up (p=0.006), and longer duration
between the last clinical assessment to death (p<0.001).

Author Manuscript

Table 2 shows the prevalence of the six pathology patterns, frequency of the NFT and plaque
categories by pathology patterns, observed number of clinical diagnoses of AD and vascular
dementia, presence of Lewy body pathology, and the prevalence of APOE-ε4 allele
(proportion of subjects with at least one ε4 allele) by the six pathology patterns. Moderate
AD pathology (58%) was the dominant pattern. We also provided separate columns for: (a)
neocortical Lewy body pathology [34, 35] and (b) primary age-related tauopathy, or PART
[36], which was defined here as CERAD plaque stage of none or sparse with Braak stage of
III or above, due to the tendency of these pathologies to mimic the clinical symptoms of AD.
About 23% of subjects in this study (245 of 1054) had a clinical AD diagnosis during follow
up, and 6% (60 of 1054) were diagnosed with probable or possible vascular dementia. Lewy
body pathology was seen among 19% of the participants (204 of 1054), and among them
44.6% (91 of 204) had neocortical Lewy body disease. Neocortical Lewy body disease
among those with clinical AD was rare when the AD pathology rating was low but was seen
in about 20% of subjects with clinical AD when the AD pathology rating was moderate or
severe. PART accounted for 13.5% (33 of 245) of clinical AD cases. APOE-ε4 prevalence
increased as the level of AD pathological burden increased: 12% among those with low AD
pathology, 20% among those with moderate AD pathology, 36% among those with high AD
Alzheimers Dement. Author manuscript; available in PMC 2018 June 01.
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pathology without lacunes and large infarcts, and 49% among those with high AD pathology
with lacunes and/or large infarcts. As expected, incident clinical AD was more likely to have
occurred among those with high AD pathology, with over 50% of those with high AD
pathology diagnosed with clinical AD during the follow-up.
Table 3 shows the logistic regression results for the factors associated with missing autopsy
data. Older age at death, white race, and higher education were associated with lower
likelihood of missing autopsy, while longer duration from the last observation to death was a
positive predictor of missing autopsy, confirming that the MAR assumption was reasonable
in our data, although we cannot exclude the possibility that the missing data pattern was
nonignorable (i.e., informative dropout).
Main results

Author Manuscript
Author Manuscript
Author Manuscript

Education, sex, presence of APOE-ε4 and Lewy body pathology were controlled for in
Model 1 with age as the time scale, and we further added center indicators in Model 2 (Table
4). For each AD pathology level (low, moderate and high), we assessed whether having
lacunes and/or large infarcts posed an excess risk of a clinical diagnosis of AD by comparing
the hazard rate for AD pathology only with that for AD pathology with vascular factors. In
Model 1, all other pathology patterns showed a higher risk of being diagnosed with clinical
AD in comparison with low AD pathology without lacunes and large infarcts (reference
group), with adjusted hazard ratios (HR) ranging from 2.6 (moderate AD pathology without
lacunes and large infarcts) to 8.6 (high AD pathology without lacunes and large infarcts).
The additional risk posed by lacunes or large infarcts was significant among those with low
AD pathology (p=0.017) and moderate AD pathology (p=0.018), but was not significant
among those with high AD pathology (p=0.199), suggesting that once AD pathology
becomes definitive, having lacunes or large infarcts does not add to the risk of being
diagnosed with clinical AD. In Model 2, controlling for center effects attenuated the
additional risks posed by lacunes and large infarcts. We found an additional risk posed by
these vascular factors only among those with low AD (p=0.012). Regarding the center
effects, significant variability was found across centers: in comparison with Oregon cohorts
(the reference group), the Rush cohort showed a higher likelihood of having incident clinical
AD diagnosis (HR=1.73, p<0.01), while the Washington University cohort showed a lower
likelihood (HR=0.27, p<0.01). The Kentucky and Oregon cohorts were similar regarding the
risk of incident clinical AD diagnosis. Regarding other covariates, Lewy body pathology
was consistently significantly associated with an increased risk of clinical AD regardless of
models or with/without imputation with an HR of 1.5. Finally we calculated PAR% using
the coefficients derived from Table 4 Model 2, and the prevalence of pathology types
reported in Table 2. PAR% ranged from 14% (low AD pathology with lacunes and/or large
infarcts) to 45% (high AD pathology without lacunes and large infarcts). Overall, an
estimated 89% of clinical AD could be eliminated by preventing all five AD pathology
patterns (patterns from (2) to (6)). Additionally, 9.5% of clinical AD could be eliminated by
preventing Lewy body pathology. Excess risk of clinical AD posed by vascular factors was
only significant among the low AD pathology group: the proportion of clinical AD
attributable to lacunes or large infarcts was estimated as 14.3% or less.
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To address potential selection bias from using only autopsied participants, we also imputed
pathology types in a sensitivity analysis. The results are listed in Table 4. The imputation did
not yield any notable changes to the main results reported in Model 2; again additional HRs
(excess risk) associated with lacunes and/or large infarcts were only significant among those
with low AD pathology (p=0.02). Using the imputed pathologies, the center effect of
Washington University became insignificant, i.e., their participants’ risk of incident clinical
AD was similar to Oregon’s.
Post-hoc analyses

Author Manuscript

The six pathology patterns used in the study were based on 1991 criteria of Braak and Braak
[17]. Braak et al. modified the criteria for the use of immunohistochemistry [37]; the
modified criteria were tested in a large European multicenter study, and it was concluded
that at least moderate severity of neuropil threads/NFTs is needed to count an area positive
for most Braak stages [38]. Therefore, we limited these analyses to cases autopsied after
January of 2006 and examined what proportion of those cases with high AD pathology with
or without lacunes and large infarcts had clinical diagnosis of AD. Out of 104 cases with
high AD pathology (pathology patterns (5) and (6) defined here), 73% (n=76) had diagnosis
of clinical AD and additional 13% (n=14) had other types of dementia (vascular, Dementia
with Lewy bodies, and frontotemporal dementia). Cox proportional hazard models were also
run using only subjects autopsied after 2006. The results are included in Supplemental Table
1. The HRs for AD pathology increased in magnitude, indicating closer correspondence
between AD pathology and clinical diagnosis of AD. The results regarding contribution of
lacunes and large infarcts remained unchanged.

Author Manuscript

To delineate further the effect of vascular factors on clinical dementia incidence, we ran an
additional model with the outcome of overall dementia using observed data (Table 5).
Lacunes and large infarcts posed excess risk among those with low AD pathology (p=0.01)
as well as those with moderate AD pathology (p=0.04). The HRs ranged from 1.81
(moderate AD pathology without lacunes or large infarcts) to 6.11 (high AD pathology
without lacunes or large infarcts). Up to 34% of overall dementia could be eliminated by
preventing lacunes and large infarcts based on the PAR% using HRs for which the vascular
contribution was shown to be significant. Combined PAR% showed that about 74% of
overall clinical dementia could be eliminated by preventing AD pathology patterns
examined here, and an additional 10% could be eliminated by preventing Lewy body
pathology.

Author Manuscript

DISCUSSION
There is growing interest in the influence of vascular factors on clinical AD incidence
[3-12]. Using harmonized pathology data derived from well-characterized community
cohorts followed at ADCs in the United States, we assessed whether coexistence of vascular
factors posed additional risk of an incident clinical diagnosis of AD beyond the risk
associated with AD pathology, and to what extent clinical diagnosis of AD could be
prevented by eliminating lacunes and large infarcts. There are several noteworthy findings.
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First, the prevalence of clinically diagnosed AD increased as the severity of AD pathology
increased from 4.2% (among low AD pathology group) to 53.3% (among high AD
pathology group), showing high correlations of plaques and tangles with overall clinical AD
incidence. Yet about half of the participants died without clinical AD diagnosis, despite
having high AD pathology. This result coincides with previous studies among community
samples [14] [39], showing between one-third and one-half of community samples may die
without having a clinical AD diagnosis, despite autopsy findings of moderate or high AD
pathology. Ours and these latter studies are based on 1991 Braak criteria [17]. Limiting the
samples to those autopsied after 2006 , i.e., the cases likely assessed based on newer criteria
[37], we found a higher proportion (73%) of those with high AD pathology had clinical
diagnosis of AD. This proportion is still lower than those found among clinical samples [40].
This discrepancy may be due, in part, to the fact that some cases after 2006 were still
measured by the older Braak criteria. It is also possible that our study subjects were drawn
from highly educated and healthy volunteers who likely had increased cognitive reserve
relative to clinical samples. Additionally, informants were not always available in the
community samples, which might have led to an underestimation of cognitive problems. All
explanations are limited to speculations at this point.

Author Manuscript

One important question is whether these participants with moderate and high AD pathology
would have been diagnosed with clinical AD during their lifetime, had they lived longer. In
our imputed data, we found that 40.8% of those with moderate or high AD pathology
without an observed diagnosis of clinical AD or dementia had an imputed age of AD onset
within three years after their date of death. In other words, we estimated that 40% of
participants who died without a clinical AD diagnosis, despite having moderate or high AD
pathology, would have been diagnosed if they had lived longer. If life expectancy among the
oldest old age group increases, the prevalence of AD could increase sharply unless advances
in the prevention and treatment of AD are also made. Regarding the PAR%, an estimated
89% of incident clinical AD cases could be prevented by eliminating AD pathology, either
alone or in combination with lacunar and large infarcts. The PAR% estimates of the
moderate and high AD pathology groups were similar due to higher prevalence of those with
moderate AD pathology despite their lower hazard of clinical AD. Regarding overall
dementia (i.e., including all sub-types of dementia), 75% of incident cases could be
prevented by eliminating AD pathology. We expect the contribution of vascular factors on
vascular dementia incidence is large, but our small sample size precluded us from estimating
HRs using vascular dementia as the outcome.

Author Manuscript

Second, in the harmonized data used in this study, the mean age at death was about 90 years
old, and the excessl risk of clinical AD posed by the coexistence of lacunes and large
infarcts was relatively small; a significant contribution was only observed among those with
low AD pathology. It is well established that the prevalence of mixed dementia increases as
age increases [5, 12, 13, 41-43]. However, we found having AD pathology without lacunes
and large infarcts was more prevalent in the participants examined here, with 60% having
AD pathology (combining low, moderate and high) without lacunes or large infarcts in
comparison to 40% with these vascular factors. Meta-analyses of epidemiological studies
have shown that vascular diseases and vascular disease risk factors in midlife are risk factors
of AD in later life [1, 2, 4]. Clinical expression of AD could be promoted via cardio- and
Alzheimers Dement. Author manuscript; available in PMC 2018 June 01.
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cerebrovascular diseases, possibly due to reduced cognitive reserve, but the vascular and AD
pathological developments could be independent [44-46], although the latter has not been
proven. Our results support previous findings [47, 48] that reinforced the diagnostic
importance of AD pathology in clinical AD, as well as a more recent finding among those
aged 90 years and older [49]. It is possible that clinicians tend to give a diagnosis of possible
vascular dementia if they see lacunes and especially large infarcts on neuroimaging, which
may underestimate the vascular contribution of clinical AD. Incidence of vascular dementia
in our data was relatively low (about 12% out of those diagnosed with any dementia were
diagnosed with vascular dementia), limiting the overall contribution of lacunes and large
infarcts at population level. Our finding that the significant additional risk posed by lacunes
and large infarcts occurred only among those with low AD pathology also confirms earlier
findings by Boyle et al. (e.g., Figure 3 in [50]) and Schneider et al. (Figure 1 and 2 in [51]),
where the authors found that the variability of cognitive decline explained by vascular
factors was more prominent when the severity of AD pathologies was lower. If the presence
of vascular pathology promotes the accumulation of AD pathology [52, 53], then the
underlying contribution of vascular factors on overall AD incidence is much higher.
However, this causal relation cannot be ascertained using our dataset since autopsy data
cannot provide the time order of pathological events. One notable limitation in our analysis
is that we did not examine micro-infarcts [54] due to the necessity to harmonize data across
sites, which could have led to an underestimation of the prevalence of vascular factors.
Further harmonization of assessment approaches for micro-infarcts and other vascular
markers in our data could address this issue in the future [54].

Author Manuscript

Third, about 15% (n=167) of participants had low AD pathology without lacunes or large
infarcts, and among them 21 (2% of the total) were found to have no NFTs and no neuritic
plaques (data not shown), confirming that even among our participants, who had a mean age
at death of 90 years old, it was possible, if rare, to remain free from these pathologies.
Comparing these participants with others regarding their genetic, premorbid neuroimaging
and other biomarker results could reveal some key factors relating to aging free from AD
pathological development.

Author Manuscript

Fourth, we found significant center effects. The cohorts followed by Rush University
(located in Chicago, IL, USA) had a higher hazard of diagnosed AD compared with the
cohorts followed in Oregon (located in Portland, OR, USA) and Kentucky (located in
Lexington, KY, USA), while the Washington University cohort (located in St. Louis, MO,
USA) had a lower hazard of incident AD, although the latter was not found when using
imputed data. These differences were seen after controlling for pathological characteristics,
i.e., given the same levels of AD pathology, lacunes and large infarcts, Lewy body
pathology, and APOEε4 contributions. Unlike the diagnosis of MCI, the diagnostic
procedure of AD is well harmonized across centers, but there may still be some variability
depending on, for example, whether biomarker information was used in consensus
diagnoses. The center differences could also be due to differences in susceptibility to AD
symptoms by cohort, including racial compositions as well as lifestyle factors and
environment.
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Finally, selection bias in the autopsied group could distort study results. For example, if
those who die without dementia are less likely to come to autopsy, then this could
potentially overestimate the association between pathology and AD incidence. In the current
study, using imputed pathology data did not change the main results. The magnitude of bias
associated with missing autopsy data is likely to depend on the cohorts examined in the
study. We advise researchers to conduct sensitivity analyses when analyzing autopsy data to
examine the potential selection bias.

Author Manuscript

Limitations of this study include: all cohorts included in this study are community-based,
but they are not a random sample of the community. Generalizability of the results may be
limited. Data harmonization requirements excluded some variables from the analyses that
were found to explain variability in cognitive decline in other papers, including hippocampal
sclerosis [47, 55, 56], TDP-43 proteinopathy [55-57], microinfarcts [54], cerebral amyloid
angiopathy [58], and arteriolosclerosis and atherosclerosis [59]. We could not differentiate
the location of infarcts and its effects on clinical diagnosis of AD. Despite these
shortcomings, the data used here have the advantage of providing a relatively large sample
size, adequate longitudinal follow-up, and multicenter data not limited to a specific
geographic region, which increases generalizability. Continuation and expansion of the
pathology consortium and improvement of standardized neuropathological assessment
criteria are strongly encouraged to further advance our understanding of biological
mechanisms and cognitive functions over time.
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Table 1

Author Manuscript

Characteristics of participants who died during follow-up with or without autopsy (N=1566)
Parameters

With Autopsy
N=1054

P-value#

Without Autopsy
N=512*

Mean (continuous
variable) or N
(categorical
variable)

STD
(continuous
variable) or
%
(categorical
variable)

Mean (continuous
variable) or N
(categorical
variable)

STD (continuous
variable) or
% (categorical
variable)

88.53

7.26

89.49

7.31

0.014

Women: n %

666

63.2

314

61.33

0.48

Race: White % (vs. Non-White)

1039

98.7

469

91.6

<0.001

Education, years: mean, std

15.9

3.43

14.39

3.46

<0.001

APOE (having at least one ε4 allele):
n%

233

22.10

117

22.85

0.74

Duration of follow-up, years:
mean,std

7.84

4.73

6.92

5.14

0.006

Duration between last observation to
death, years: mean, std

0.96

1.29

1.83

2.22

<0.001

Age at death, years: mean, std

Author Manuscript

Centers: n %

<0.001

Oregon

113

10.72

190

37.11

Rush

549

52.09

114

22.27

Washington U

122

11.57

154

30.08

Kentucky

270

25.62

54

10.55

#

: based on univariate analysis

*

: including a small proportion of subjects (n=77) who had autopsy, but missing some of pathology variables of our interests

Author Manuscript
Author Manuscript
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167
(15.8)

90
(8.5)

347
(32.9)

267
(25.3)

105
(10.0)

78
(7.4)

(2) Low AD
pathology
with
lacunes and/or
large
infarcts

(3) Moderate
AD
pathology
without
lacunes
and large
infarcts

(4) Moderate
AD
pathology
with
lacunes
and/or
large
infarcts

(5) High AD
pathology
without
lacunes
and large
infarcts

(6) High AD
pathology

N
(%)

(1) Low AD
pathology
without
lacunes
and large
infarcts

Pathology
Patterns: n %

Alzheimers Dement. Author manuscript; available in PMC 2018 June 01.
0

0

0

0

90

167

Plaque
no or
sparse

0

0

36

63

0

0

Plaque
moderate/
frequent

Braak
None or Stage
I or II

0

0

86

118

0

0

Plaque
no or
sparse

0

0

136

155

0

0

Plaque
moderate/
frequent

Braak
Stage III or IV

0

0

0

11

0

0

Plaque
no or
sparse

78

105

0

0

0

0

Plaque
moderate/
frequent

Braak
Stage
V or VI

40
(51.3)

56
(53.3)

71
(25.6)

57
(16.4)

14
(15.6)

7
(4.2)

All

0

0

17
(23.9)

16
(28.1)

0

0

With
PART*
(% of all)

9
(22.5)

11
(19.6)

11
(15.4)

11
(19.2)

0

2
(0.3)

Neocortical
Lewy Body
(% of all)

Clinical Diagnosis of
Probable or Possible
AD

Author Manuscript

Pathology Patterns and Associated Characteristics

12
(15.4)

8
(7.6)

23
(8.6)

12
(3.5)

4
(4.4)

1
(0.6)

All

0

0

7
(30.4)

2
(16.7)

0

0

With
PART*
(% of all)

Clinical
Diagnosis of
Probable or
Possible
Vascular
Dementia

23
(29.5)

31
(29.5)

52
(19.5)

69
(19.9)

13
(14.4)

16
(9.6)

All

12
(52.2)

17
(54.8)

21
(40.4)

34
(49.3)

2
(15.4)

5
(31.3)

Neocortical
Lewy Body
(% out all)

Lewy Body
Pathology
Present

Author Manuscript

Table 2

38
(48.7)

38
(36.2)

52
(19.5)

74
(21.3)

11
(12.1)

20
(12.0)

Apoe 4
present

Dodge et al.
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1054

Plaque
moderate/
frequent

Plaque
no or
sparse

Plaque
moderate/
frequent

Plaque
no or
sparse

Plaque
moderate/
frequent

Braak
Stage
V or VI

245

All

33

With
PART*
(% of all)

44

Neocortical
Lewy Body
(% of all)

Clinical Diagnosis of
Probable or Possible
AD

60

All

9

With
PART*
(% of all)

Clinical
Diagnosis of
Probable or
Possible
Vascular
Dementia

204

All

91

Neocortical
Lewy Body
(% out all)

Lewy Body
Pathology
Present

233

Apoe 4
present

PART: Primary Age-Related Tauopathy.

*

Low AD pathology: Braak = no neurofibrillary degeneration present or Stage I or II & Neuritic plaque =none or space. High AD pathology: Braak=Stage V or VI & Neuritic plaque = Moderate or Frequent,
Moderate AD pathology: those not falling into the above two categories.

Total

with
lacunes and/or
large
infarcts

Plaque
no or
sparse

Braak
Stage III or IV

Author Manuscript
Braak
None or Stage
I or II

Author Manuscript

N
(%)

Author Manuscript

Pathology
Patterns: n %
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Table 3

Author Manuscript

Logistic regression model with missing autopsy as the outcome
Parameter (OR unit difference)

OR

95% CI

p-value

Age at death (1 year)

0.98

0.96 - 1.00

0.02

Female (vs. Male)

0.86

0.67 - 1.11

0.26

Race (White vs. Non-White)

0.26

0.13 - 0.52

<0.01

Education (1 year)

0.95

0.91 - 0.99

<0.01

APOE (having at least one ε4 allele vs
no ε4 allele)

1.10

0.82 - 1.47

0.55

Duration of follow-up (1 year)

0.98

0.96 - 1.01

0.23

Duration from the last observation to
death (1 year)

1.35

1.25 - 1.47

<.0001

Onset of clinical AD observed during
the follow-up (vs. censored)

1.06

0.76 - 1.48

0.73

Author Manuscript

Center effects were controlled in the model.
The number of subjects who did not have autopsy =435, the number of subjects who had autopsy = 1131 (1054+ 77).

Author Manuscript
Author Manuscript
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45.2%

43.5%

35.8%

14.3%

Ref

.....Rush

Oregon

Center Effects:
Ref
1.67 (1.25-2.23)**

Ref
1.73 (1.16-2.59)**

88.7%

(5) vs
(6)P=0.930

(3) vs (4)
P=0.190

(1) vs(2)
P=0.020*

Combined PAR# (pathological
patterns 2, 3, 4, 5 and 6)

5.41 (2.60-9.75)**

5.30 (2.60-10.78)**

2.39 (1.27-4.49)*

1.89 (1.00-3.62)*

2.38 (1.16-4.87)*

Ref

9.5%

33.4%

5.91 (2.57-13.61)**

(5) vs (6)
P=0.504

(3) vs (4)
P=0.115

(1) vs(2)
P=0.012*

1.49 (1.19-1.87)**

1.42 (1.12-1.80)**

1.02 (0.99-1.05)

0.95 (0.75-1.19)

PAR%
Based on
Model 2
and
observed
prevalence

(6) High AD pathology with
lacunes and/or large
infarcts
6.55 (2.86-14.99)**

6.82 (3.03-15.38)**

(5) vs (6)
P=0.199

8.57 (3.82-19.22)**

(5) High AD pathology without
lacunes and large infarcts

2.72 (1.22-6.06)*

3.90 (1.76-8.63)**

(4) Moderate AD pathology
with lacunes and/or large
infarcts

2.04 (0.91-4.57)

2.55 (1.15-5.69)*

(3) vs (4)
P=0.018*

(3) Moderate AD pathology
without lacunes and large
infarcts

3.19 (1.27-8.05)*

3.03 (1.20-7.64)*

(2) Low AD pathology with
lacunes and/or large
infarcts

(1) Low AD pathology without
lacunes and large infarcts

Ref

1.54 (1.16-2.05)**

1.59 (1.20-2.11)**

Lewy Body Pathology (yes vs.
no)

(1) vs(2)
p=0.017*

1.36 (1.00-1.85)*

1.34 (0.99-1.81)

APOE ε4 (having at least one ε4
allele vs no ε4 allele)

Ref

1.03 (0.99-1.07)

1.07 (1.03-1.11) **

Education (1 year)

Pathology patterns

0.91 (0.68-1.22)

1.02 (0.77-1.35)

Difference
in
Coefficient
p-value

Hazard
Ratio (95% CI)

Hazard Ratio
(95% CI)

Difference in
Coefficient
p-value

Hazard Ratio
(95% CI)
Sensitivity
Analysis

Model 2

Model 1

Difference in
Coefficient
p-value

Including Imputed Data

Using Observed Data Only

Female (vs. Male)

Parameter

Results of Cox Proportional Hazard Model with Pathology Patterns as Independent Variables with Outcomes being Incidence of Clinical AD

Author Manuscript

Table 4
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0.81 (0.54-1.21)
1.08 (0.76-1.53)

0.27 (0.13-0.57)**
0.82 (0.51-1.31)

.....Washington U
.....Kentucky

: Calculated using the formula:

#

PAR% was calculated by using formula: (prevalence × (RR-1))/(1+(prevalence × (RR-1))

: p<0.01

**

: p<0.05,

*

Difference
in
Coefficient
p-value

Hazard
Ratio (95% CI)

Difference in
Coefficient
p-value

Hazard Ratio
(95% CI)

Difference in
Coefficient
p-value

Hazard Ratio
(95% CI)
Sensitivity
Analysis

Model 2

Model 1

Author Manuscript
Including Imputed Data

Author Manuscript

Using Observed Data Only

Author Manuscript

Parameter

PAR%
Based on
Model 2
and
observed
prevalence

Dodge et al.
Page 20
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Table 5

Author Manuscript

Results of Cox Proportional Hazard Model with Pathology Patterns as Independent Variables with Outcomes
being Incidence of Overall Dementia
Parameter

Using Observed Data Only
Hazard Ratio
(95% CI)
Overall Dementia

Female (vs. Male)

0.90 (0.69-1.18)

Education (1 year)

1.02 (0.99-1.06)

APOE ε4 (having at least one
ε4 allele vs no ε4 allele)

1.37 (1.04-1.82)*

Lewy Body Pathology (yes
vs. no)

1.57 (1.21-2.04)**

Difference
in
Coefficient
p-value

PAR%
Overall Dementia

9.9%

Pathology patterns

Author Manuscript
Author Manuscript

(1) Low AD pathology
without lacunes and
large infarcts

Ref

(2) Low AD pathology with
lacunes and/or large
infarcts

2.77 (1.26-6.10)*

(3) Moderate AD pathology
without lacunes and
large infarcts

1.81 (0.92-3.59)

(4) Moderate AD pathology
with lacunes and/or
large infarcts

2.56 (1.30-5.05)**

(5) High AD pathology
without lacunes and
large infarcts

6.11 (3.06-12.20)**

(6) High AD pathology with
lacunes and/or large
infarcts

5.64 (2.78-11.42)**

(1) vs(2)
P=0.010*
6.1%

(3) vs (4)
P=0.042*

21.0%

28.3%

(5) vs (6) P=0.678

Combined PAR# (pathology
patterns (2), (3), (4), (5) and (6)
listed above)

33.8%

25.6%

73.8%

Center Effects:
Oregon cohorts

Ref

.....Rush

1.48 (1.02-2.15)*

.....Washington U

0.73 (0.44-1.20)

.....Kentucky

0.99 (0.65-1.51)

*

: p<0.05,

**

: p<0.01

Author Manuscript

PAR% was calculated by using formula: (prevalence × (RR-1))/(1+(prevalence × (RR-1))

#

: Calculated using the formula:
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